# 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

> **NCT04566978** · EARLY_PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Large B-cell Lymphoma
- DLBCL

## Interventions

- **DRUG:** 89Zr-DFO-REGN3767
- **DIAGNOSTIC_TEST:** PET/CT

## Key facts

- **NCT ID:** NCT04566978
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-11
- **Primary completion:** 2025-03-21
- **Final completion:** 2025-03-21
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566978, "89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04566978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*